Lupin Completes Acquisition of VISUfarma, Expands European Presence
Filing Summary
Lupin Limited has finalized the acquisition of VISUfarma B.V., a European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP. This acquisition enhances Lupin’s ophthalmology portfolio to over 60 branded products and strengthens its market presence in key European countries such as Italy, the UK, Spain, Germany, and France. VISUfarma generated €53 million in revenue in 2025. The acquisition aligns with Lupin’s strategy to expand its specialty care portfolio and address the growing demand for eye care solutions.
Lupin Limited has announced the completion of its acquisition of VISUfarma B.V., a European specialty pharmaceutical company focused on ophthalmology. The acquisition was made from GHO Capital Partners LLP. This strategic move is part of Lupin’s plan to expand its specialty care portfolio and strengthen its presence in the European market.
The acquisition of VISUfarma significantly expands Lupin’s ophthalmology portfolio, which now includes over 60 branded products. These products cover areas such as dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals. VISUfarma’s commercial operations are well-established in key European markets, including Italy, the UK, Spain, Germany, and France. In 2025, VISUfarma generated €53 million in revenue, highlighting its strong market position and potential for growth under Lupin’s ownership.
The integration of VISUfarma into Lupin’s operations enhances the company’s ability to meet the increasing global demand for innovative eye care solutions. This demand is driven by factors such as an ageing population and the rising incidence of diabetes-related eye complications. The acquisition also brings a highly experienced team with deep expertise in ophthalmology, trusted relationships, and strong local market insights, further strengthening Lupin’s position in the European market.
The acquisition was completed on April 2, 2026. Lupin’s CEO, Vinita Gupta, emphasized that the acquisition adds a differentiated portfolio of more than 60 innovative eye health products supported by an established commercial infrastructure. The acquisition is expected to expand Lupin’s presence across Europe and accelerate the development of its specialty franchise.
VISUfarma was founded in 2016 through the combination of the Italian company Visufarma SpA and the European commercial activities of Nicox SA. The company focuses on ophthalmology and has a strong commercial footprint in Europe. VISUfarma was acquired by GHO Capital in 2016, and its integration into Lupin marks a new chapter in its growth and development.
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India. The company specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin operates in over 100 markets and has a strong presence in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin is committed to improving patient health outcomes through its subsidiaries, including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.